Waller C, Vicariot M, Gunzberger H
Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg.
Transfus Clin Biol. 1997 Dec;4(6):541-8. doi: 10.1016/s1246-7820(97)80079-1.
The principal result of the development of hemovigilance since 1994 has been the declaration of undesirable effects likely to be due to transfusions of labile blood products. Using the 1,694 cases of undesirable effects registered, it seemed worthwhile to us to analyze the distribution of the signs noticed, their frequency and the types of blood products responsible. This analysis allowed us to observe that the majority of reactions were shivery-feverish (47%) or allergic (24%). Most of them are linked to platelet concentrate transfusions especially simple donor platelets (with a frequency of ten reactions for thousand apheresis platelet concentrates transfused). In this study the frequency of undesirable effects reported is 2 per 1,000 apheresis platelet concentrate transfusions. Further investigations are necessary to determine the physiological mechanisms of these reactions and to estimate the degree to which transfusions are responsible for their occurrence.
自1994年开展血液警戒以来的主要成果是，发现了可能由输注不稳定血液制品导致的不良反应。利用登记的1694例不良反应病例，我们认为分析所观察到的体征分布、其发生频率以及相关血液制品类型是有价值的。该分析使我们观察到，大多数反应为寒战发热（47%）或过敏（24%）。其中大多数与浓缩血小板输注有关，尤其是单纯供体血小板（每输注1000个单采血小板浓缩物会出现10次反应）。在本研究中，报告的不良反应发生率为每1000次单采血小板浓缩物输注2例。有必要进一步研究以确定这些反应的生理机制，并评估输血在其发生过程中的责任程度。
